Advertisement

Research Article Free access | 10.1172/JCI114668

Identification of surface proteins mediating adherence of CD11/CD18-deficient lymphoblastoid cells to cultured human endothelium.

B R Schwartz, E A Wayner, T M Carlos, H D Ochs, and J M Harlan

Department of Medicine, University of Washington, Seattle 98195.

Find articles by Schwartz, B. in: PubMed | Google Scholar

Department of Medicine, University of Washington, Seattle 98195.

Find articles by Wayner, E. in: PubMed | Google Scholar

Department of Medicine, University of Washington, Seattle 98195.

Find articles by Carlos, T. in: PubMed | Google Scholar

Department of Medicine, University of Washington, Seattle 98195.

Find articles by Ochs, H. in: PubMed | Google Scholar

Department of Medicine, University of Washington, Seattle 98195.

Find articles by Harlan, J. in: PubMed | Google Scholar

Published June 1, 1990 - More info

Published in Volume 85, Issue 6 on June 1, 1990
J Clin Invest. 1990;85(6):2019–2022. https://doi.org/10.1172/JCI114668.
© 1990 The American Society for Clinical Investigation
Published June 1, 1990 - Version history
View PDF
Abstract

Patients with the severe form of leukocyte adhesion deficiency syndrome do not express the CD11/CD18 adhesion complex on any of their leukocytes. Nevertheless, their lymphocytes, unlike their phagocytes, emigrate to extravascular sites of inflammation, demonstrating that surface proteins other than CD11/CD18 can mediate lymphocyte adherence to endothelium. Using a B-lymphoblastoid cell line (B-LCL) established from a CD11/CD18-deficient patient and cultured human umbilical vein endothelial cells (HEC), we investigated the CD11/CD18-independent mechanism(s) of lymphocyte adherence to endothelium. Monoclonal antibodies directed to the alpha 4 polypeptide (CD49d) and the beta 1 polypeptide (CD29) of the lymphocyte VLA-4 integrin receptor (CD49d/CD29), and to vascular cell adhesion molecule-1 (VCAM-1) on the endothelial cell significantly inhibited the adherence of the CD11/CD18-deficient B-LCL to untreated HEC and to HEC treated with recombinant human tumor necrosis factor-alpha. We suggest that the interaction of the lymphocyte receptor VLA-4 with the endothelial ligand VCAM-1 induced by cytokines at sites of inflammation or immune reaction represents a CD11/CD18-independent pathway of lymphocyte emigration.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (June 1, 1990): No description
Advertisement
Advertisement